Clinical Pharmacology – Biomolecular
End-to-End Hot Topic
In contrast with cytotoxic and targeted oncology agents that target tumor cells directly, immuno-oncology agents act indirectly by mobilizing the host immune system to eradicate tumor cells. The talk will focus on unique clinical pharmacology considerations for immuno-oncology agents. Examples from the currently approved immune checkpoint inhibitors will illustrate how clinical pharmacology provided pivotal supportive information during development and approval.